Forest Labs Settles BYSTOLIC Patent Lawsuit

Forest Laboratories (NYSE: FRX  ) announced today it has agreed to settle the patent infringement lawsuit it had brought against Glenmark Generics. That litigation was in response to Glenmark's seeking approval to produce a generic version of Forest's hypertension drug, BYSTOLIC (generic name, nebivolol).

Under the terms of the agreement, Glenmark will not be allowed to produce its version of nebivolol prior to three months before Forest's patent expires.

This settlement is just one more agreement Forest has made with companies seeking to produce generic versions of BYSTOLIC. Forest made previous settlement agreements with Hetero Labs, Alkem Laboratories, Indchemie Health Specialities, and Torrent Pharmaceuticals.

Forest still has BYSTOLIC patent infringement litigation pending against Amerigen Pharmaceuticals and Watson Pharmaceuticals (NYSE: ACT  ) .

link


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2178015, ~/Articles/ArticleHandler.aspx, 11/28/2014 5:00:26 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement